Skip to main content

Table 3 Change in whole blood cells, lymphocyte, neutrophil levels, MID and platelet counts between pre-treatment and the post-treatment for the three groups (n = 92)

From: Selective intra-arterial infusion of rAd-p53 with chemotherapy for advanced oral cancer: a randomized clinical trial

  Groupa P-value
I (n = 33) II (n = 30) III (n = 29)
UICC stage III, n 10 8 8  
UICC stage IV, n (%) 23 (70) 22 (73) 21 (72)  
Whole blood cell count, mean ± SD    
 UICC stage III -0.11 ± 0.54e -0.04 ± 0.29c -2.34 ± 0.74cde <0.001b
 UICC stage IV -1.19 ± 0.73e -0.03 ± 0.35c -2.06 ± 0.75cde <0.001b
Lymphocyte levels     
 UICC stage III -0.68 ± 0.34e 0.21 ± 0.59c -0.91 ± 0.41de <0.001b
 UICC stage IV -0.77 ± 0.46e 0.23 ± 0.54c -1.02 ± 0.57de <0.001b
Neutrophil granulocytes, mean ± SD    
 UICC stage III -0.38 ± 0.63 -0.33 ± 0.47 -1.16 ± 0.56de 0.015b
UICC stage IV -0.35 ± 0.50e -0.36 ± 0.52e -0.86 ± 0.63cde 0.004b
MID, mean ± SD    
 UICC stage III -0.15 ± 0.22 0.10 ± 0.24 -0.29 ± 0.25de 0.013b
 UICC stage IV -0.07 ± 0.23 0.05 ± 0.23 -0.17 ± 0.18de 0.005b
Platelet counts, mean ± SD    
 UICC stage III -22.20 ± 70.85 -23.00 ± 22.01e -25.57 ± 27.09e 0.990
 UICC stage IV -54.09 ± 35.46e -7.68 ± 19.49c -23.91 ± 29.30cde <0.001b
  1. Abbreviations: MID, minimum inhibitory dilution (which measures rare cells and precursor white cells); UICC, International Union Against Cancer.
  2. aGroup I: chemotherapy and rAd-p53; group II: rAd-p53; group III: chemotherapy.
  3. bStatistically significant difference between the three treatment groups.
  4. cStatistically significant difference between the indicated treatment group and group I.
  5. dStatistically significant difference between groups II and III.
  6. eStatistically significant difference between pre-treatment and post-treatment stages of each group by paired t-test.
\